Dr. Blob has over 22 years of clinical trial experience. He has obtained board certification in both Internal Medicine and Emergency Medicine and has provided medical oversight of clinicals trial from a Principal Investigator, Pharmaceutical Company and CRO perspective. He taught and practiced emergency medicine from 1980 to 1998. During this time, he founded and ran two small healthcare companies. In 1998 he opened a phase 1 research center and conducted numerous studies that supported the FDA approval of EMSAM, the transdermal selegiline system developed to treat major depression. Dr. Blob became the Medical Director of Somerset Pharmaceuticals, Inc. in 2002 and was the primary presenter to the FDA Psychopharmacological Advisory Committee in October 2006.

Dr. Blob is a co-author of several scientific articles pertaining to tyramine sensitivity and has presented tyramine safety data both nationally and internationally. Dr. Blob received his B.S. Biology from Loyola College, and his MD and Post Graduate Training from the University of Maryland.